Is also Beth Karlan, named editor-in-chief of the Society of Gynecologic Oncology ‘Medical JournalBeth Y. Director of the Cedars-Sinai Women’s Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute and an acknowledged expert in the field of gynecologic Oncology, was named the new Editor-in-Chief of Gynecologic Oncology, the medical journal of the society of Gynecologic Oncology .
Congress stated, for for cancer research women.
1)bsidiary PLIVA Receives Approval for Generic Zithromax IV, 500 mg VialBarr Pharmaceuticals and its subsidiary PLIVA dd today announced that PLIVA did make the final approval by the U.S. Food and Drug Administration for its Abbreviated New Drug Application and azithromycin market for injection, received 500 mg vial, the generic version of Pfizer Labs ‘ Zithromax IV for injection. The company intends to launch their product in the first quarter of 2007.Aplenzin approved by the U.S. Food and Drug Administration in April 2008. Sanofi-aventis U.S. That licensed to Aplenzin of Biovail Corporation in December 2008, puts a product into in the U.S. And in Puerto Rico.
– bupropion, the active compound in Aplenzin features comparable potency fluoxetine, a SSRI. Bupropion also has the low incidence weight gain when compared to placebo. Research results indicate in that MDD will causes caused by an imbalance of chemicals in brain as neurotransmitter have. In the U.S. And mechanism of action Aplenzin is unknown, but it is is believed to bupropion, the active agent of Aplenzin can help restore of equilibrium of neurotransmitters that by inhibiting the reuptake of norepinephrine and dopamine.
Important Safety Information:Antidepressants increases the risk as compared to placebo for suicidal thinking and behavior in children, youth and young adults in the short-term studies of major depression and other psychiatric diseases.